Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Isabel Deisenhofer Added: 1 year ago
HRS 2024 — Prof Isabel Deisenhofer (German Heart Center Munich, Technical University of Munich, DE), investigator, joins us to discuss the findings from the TAILORED-AF trial (NCT04702451, Volta Medical).This randomised controlled trial compared a tailored ablation strategy targeting areas of patio-temporal dispersion in combination with pulmonary vein isolation (PVI) to anatomical ablation… View more
Author(s): Marco Schiavone Added: 1 month ago
EHRA 2026, Paris — Dr Marco Schiavone (Centro Cardiologico Monzino IRCCS, Milan, Italy) walks through a real-world case from his clinical practice, shining a light on the safety considerations that emerge when pulsed field ablation is applied in persistent AF — a population where procedural complexity and the stakes of adverse events are inherently higher.Drawing on instructive cases encountered… View more
Author(s): Added: 2 weeks ago
HRS Congress 2026 – Dr Christopher Porterfield (Aurora Denver Cardiology, Aurora, CO, US) discusses findings from the REAL-AF Registry, examining the safety and effectiveness of variable loop circular catheter pulsed field ablation across a broad range of patient and procedural characteristics in real-world clinical settings.The REAL-AF Registry is a prospective, multicentre, observational study… View more
Added: 1 year ago Source:  Heart Rhythm Society
SAN DIEGO, CA, APRIL 24, 2025 – Today, the Heart Rhythm Society (HRS) unveiled new research that underscores the critical role of artificial intelligence (AI) in improving procedural safety in cardiac electrophysiology (EP), demonstrating how intelligent, real-time decision support can help mitigate risks and improve clinical confidence in complex interventions. Researchers presented these… View more
Author(s): Chao Jiang , Zhao Zixu Added: 5 months ago
AHA Scientific Sessions 2025 – Dr Chao Jiang and Dr Zhao Zixu (Beijing Anzhen Hospital, CN) discuss the findings from the DARE-AF (NCT06433479) randomized clinical trial, investigating whether dapagliflozin reduces atrial fibrillation burden following catheter ablation in patients without diabetes or heart failure.This single-center, open-label trial enrolled 200 patients with persistent atrial… View more